期刊
ACS MEDICINAL CHEMISTRY LETTERS
卷 12, 期 12, 页码 1912-1919出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.1c00450
关键词
RET; receptor tyrosine kinase; KDR; pyrrolo[2, 3-d]pyrimidine; Miles assay
资金
- DOE Office of Science User Facility [DE-AC02-05CH11231]
- National Institutes of Health, National Institute of General Medical Sciences [P30 GM124169-01]
Selective inhibition of RET kinase has shown promising potential as a treatment for lung adenocarcinoma and other relevant cancer types. Compound optimization led to the discovery of a new drug with potent in vitro RET kinase inhibition and robust efficacy in RET-driven tumor xenografts in mice. Plasma exposure levels indicated minimal risk of KDR or hERG inhibition in vivo, suggesting a good tolerability profile for the compound.
The selective inhibition of RET kinase as a treatment for relevant cancer types including lung adenocarcinoma has garnered considerable interest in recent years and prompted a variety of efforts toward the discovery of small-molecule therapeutics. Hits uncovered via the analysis of archival kinase data ultimately led to the identification of a promising pyrrolo[2,3-d]pyrimidine scaffold. The optimization of this pyrrolo[2,3-d]pyrimidine core resulted in compound 1, which demonstrated potent in vitro RET kinase inhibition and robust in vivo efficacy in RET-driven tumor xenografts upon multiday dosing in mice. The administration of 1 was well-tolerated at established efficacious doses (10 and 30 mg/kg, po, qd), and plasma exposure levels indicated a minimal risk of KDR or hERG inhibition in vivo, as evaluated by Miles assay and free plasma concentrations, respectively.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据